Business
United States Patent and Trademark Office Issues U.S. Patent Covering an Enhanced Formulation of Pliaglis®
United States Patent and Trademark Office Issues U.S. Patent Covering an Enhanced Formulat...
About this update from Crescita Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nUnited States Patent and Trademark Office Issues U.S. Patent Covering an Enhanced Formulation of Pliaglis®\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nLAVAL, QC, July 16, 2019\n\n\n\nLAVAL, QC, July 16, 2019 /CNW/ - Crescita Therapeutics Inc. (\"Crescita\" or the \"Company\") (TSX: CTX) (OTC US: CRRTF), a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today announced that the United States Patent and Trademark Office (\"USPTO\") has granted U.S. Patent No. 10,350,180 for an enhanced formulation of Pliaglis® which provides extended patent protection until 2031. Related patents have also been issued worldwide with the latest expiry date in 2031.  \n\n \n \n\n \nIn April 2017, Crescita announced that it had entered into a development and commercialization license agreement (\"the Agreement\") with Taro Pharmaceuticals Inc. (\"Taro\"). Under the terms of the Agreement, Crescita granted Taro an exclusive license to the rights to sell and distribute Pliaglis as well as an enhanced formulation in the U.S. market.  \n\"The newly granted U.S. patent further strengthens our intellectual property portfolio,\" said Serge Verreault, President and CEO of Crescita. \"This patent helps broaden the platform for the commercialization of Pliaglis in the U.S. and, we believe that the additional worldwide patents will support Crescita's partnering efforts for Pliaglis in the 24 rest of world countries where the drug is approved and available for partnering.\" \nAbout CrescitaCrescita (TSX: CTX and OTC US: CRRTF) is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products for the treatment and care of skin conditions and diseases and their symptoms and prescription drug products for the treatment of pain. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that ca...